CONFERENCE PROGRAMME

Sunday, 18 October 2015		
09:00-09:10	**Opening Remarks:** *Crystal Ballroom 1&2* Publisher of *Vaccine* Alina Helsloot & Congress Co-Chairs Margaret Liu and Ted M. Ross	
09:10-10:40	**Opening Session: *Crystal Ballroom 1&2*** **Session Chairs: Margaret Liu and Joon Haeng Rhee** ***Sponsored by*** REGENERON	
09:10-09:40	**[O1.1] Vaccines and mechanisms of host defence** M.K. Slifka, *Oregon Health Sciences University, USA*	
09:40-10:10	**[O1.2] Exploring CD8+ T-cell epitope selection: Implications for immunogen design** L.S. Klavinskis, *King's College London, UK*	
10:10-10:40	**[O1.3] Therapeutic HPV 16/18 DNA vaccine, GX-188, induces a high rate of not only clearance of HPV infection, but also regression of cervical intraepithelial neoplasia III** Y.C. Sung[1], H.T. Jin[1], T.J. Kim[2], S.Y. Hur[3], J.S. Park*[3] [1]*Pohang University of Science and Technology, Republic of Korea,* *[2]Kwan Dong Medical University, Republic of Korea, [3]The Catholic University of Korea, Republic of Korea*	
10:40-11:00	**Refreshment Break** *Crystal Ballroom Foyer*	
11:00-11:30	**[O1.4] Multifaceted immunological mechanisms associated with protection in humans following oral vaccination or challenge with wild-type *Salmonella typhi*** M. Sztein, *University of Maryland, USA*	
11:30-12:00	**[O1.5] Recent progress in the development of malaria vaccines to reduce morbidity and mortality and accelerate elimination and eradication** A.J. Birkett, *PATH Malaria Vaccine Initiative (MVI), USA*	
12:00-12:30	**[O1.6] Development of a recombinant VSV-based Ebola vaccine** D. Casimiro , *Merck Research Laboratories, USA*	
12:30-13:30	**Lunch** *Crystal Ballroom Foyer* *Sponsored by* medicago	
13:30-15:40	**Breakout Session 1: Immunology of Vaccines** **Session Chairs: Natalie Garcon and Ling Chen** ***Crystal Ballroom 1***	**Breakout Session 2: Vaccine Design** **Session Chairs: Annie De Groot and Denise Doolan** ***Crystal Ballroom 2***
13:30-13:50	**[B1.1] Concomitant loss of neutralizing B cell epitopes and CD4 T cell epitopes in hemagglutinin of drifted influenza viruses** R. Powers, J. Kim, J. Jacob*, *Emory University, USA*	**[B2.1] Rational vaccine design against complex pathogens using genomic sequence data** D.L. Doolan*, C. Proietti, J. Burel, J. Roddick, A. Trieu, K. de Sousa, S.H. Apte *QIMR Berghofer Medial Research Institute, Australia*
13:50-14:10	**[B1.2] Analysis of antibody repertoire in rhesus macaques after immunization with influenza virus vaccine using NGS and a new sensitive**	**[B2.2] H7N9 T cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance**

	bioluminescent based microneutralization assay L. Chen*[1,2], X. Niu[2], C. Li[2] [1]*The First Affiliated Hospital of Guangzhou Medical University, China,* [2]*Chinese Academy of Sciences, China*	R.L. Liu[1], L.M. Moise[1,2], R.T. Tasson[1], A.G. Gutierrez[1], F.T. Terry[2], K.S. Sangare[3], M.A. Ardito[2], W.M. Martin[2], A.D.G. De Groot*[1,2] [1]*University of Rhode Island, USA,* [2]*EpiVax, Inc., USA,* [3]*University of Bamako, Mali*
14:10-14:25	**[B1.3] Intrauterine immunization using swine as an animal model** J.A. Pasternk[1], G. Hamonic[1], T. Käser[1], M.K. Dyck[2], V. Gerdts[1], H.L. Wilson*[1] [1]*University of Saskatchewan, Canada,* [2]*University of Alberta, Canada*	**[B2.3] Strategic multi-attribute ranking tool for vaccines - SMART Vaccines: informing vaccine decision making** S. Knobler*[1], C. Hoest[1], K. Bok[2], M. Miller[1], B. Gellin[2] [1]*National Institutes of Health, USA,* [2]*United States Department of Health and Human Services, USA*
14:25-14:40	**[B1.4] Co-delivery of HIV envelope protein in alum with MVA/HIV vaccine induces CXCR3-biased follicular CD4 T cell response in rhesus macaques** S. Iyer, S. Gangadhara, R. Amara* *Emory University, USA*	**[B2.4] A systems biology framework for the identification of the molecular basis of immune adjuvanticity** L.P. Trathipati*[1], T. Aoshi[1,2], Y. Igarashi[1], K. Ishii[1,2], K. Mizuguchi[1] [1]*National Institute of Biomedical Innovation (NIBIO), Japan,* [2]*Osaka University, Japan*
14:40-14:55	**[B1.5] Biomimetic vaccine formulation for effective antigen presentation and immune activation** W. Wei*, D.Z. Ni, H. Yue, G.H. Ma *Chinese Academy of Sciences, China*	**[B2.5] Identifying and exploiting toxin-derived CD4+ T cell epitopes in the design of sub-unit based vaccines against anthrax** S. Ascough*[1], R.J. Ingram[2], J.A. Musson[3], M. Doganay[4], L. Baille[5], E.D. Williamson[6], J.H. Robinson[3], B. Mailere[7], R.J. Boyton[8], D.M. Altmann[8] [1]*The Pribright Institute, UK,* [2]*Queen's University, UK,* [3]*Newcastle University, UK,* [4]*Erclyes University Hospital, Turkey,* [5]*Cardiff University, UK,* [6]*DSTL, UK,* [7]*CEA, France,* [8]*Imperial College, UK*
14:55-15:10	**[B1.6] The activating NKG2D receptor acts as a co-receptor for anti-HIV-1 antibody-dependent cellular cytotoxicity** M.S. Parsons*[1], J. Richard[3], W.S. Lee[1], M. Grant[2], A. Finzi[3], S.J. Kent[1] [1]*University of Melbourne, Australia,* [2]*Memorial University of Newfoundland, Canada,* [3]*Universite de Montreal, Canada*	**[B2.6] Design and Immunological evaluation of chimeric vaccines against *B. abortus* using SOD, BAB1_0273, BAB1_0278 proteins** A. Oñate*, E. Escalona, D. Sáez *Universidad de Concepción, Chile*
15:10-15:25	**[B1.7] Role of CCL5 ligand mediated reproductive homing pathway for Herpes nasal vaccine development** S. Joo*, A. Suwanto, A. Sato, S. Sato, Y. Kawaguchi, H. Kiyono, *The University of Tokyo, Japan*	**[B2.7] A systems level analysis of adjuvant transcriptomes for biomarker and target discovery** L.P. Tripathi*[1], J. Ito[1], T. Aoshi[1,2], K.J. Ishii[1,2], K. Mizuguchi[1] [1]*National Institutes of*

		Biomedical Innovation, Health & Nutrition, Japan, [2]Osaka University, Japan
15:25-15:40	**[B1.8] Exosome targeting DNA vaccination enhances antigen-specific CD8 T cell responses** T.K. Kanuma*[1,3], K.K. Kobiyama[2,3], K.J.I. Ishii[2,3] *[1]Osaka University, Japan, [2]WPI*	**[B2.8] Crude preparation of bacterially-produced viral subunits as a single-shot avian influenza vaccine** N. Wibowo, Y. Wu, Y. Fan, J. Meers, L.H.L. Lua*, A.P.J. Middelberg *The University of*
15:40-16:10	**Refreshment Break** *Crystal Ballroom Foyer*	
16:10-18:05	**Breakout Session 3: Immunomodulators** ***Supported by Korean Vaccine Society*** **Session Chairs: Jerome Kim and Jun Hee Woo** ***Crystal Ballroom 1***	**Breakout Session 4: Vaccines for Emerging and Re-Emerging Pathogens and Parasites** **Session Chairs: David Weiner and Peter Lijeström** ***Crystal Ballroom 2***
16:10-16:30	**[B3.1] Reposition of GM-CSF as a novel adjuvant for therapeutic vaccine to treat chronic HBV infection** B. Wang, *Shanghai Medical College and National Engineering Lab for Therapeutic Vaccines, China*	**[B4.1] The making of a Chikungunya vaccine - comparing attenuated & vectored vaccine platforms** P. Liljeström*[1], P. Roques[2,3], K. Ljungberg[1], B.M. Kümmerer[4], L. Gosse[2,3], N. Deureuddre-Bosquet[2,3], D. Hallengärd[1], J. García-Arriaza[5], M. Esteban[5], A. Merits[6], R. Le Grand[1] *[1]Karolinska Institutet, Sweden, [2]IDMIT infrastructure, France, [3]Center for Immunology of Viral Infections and Autoimmune Diseases, France, [4]University of Bonn Medical Centre, Germany, [5]Consejo Superior de Investigaciones Científicas, Spain, [6]University of Tartu, Estonia*
16:30-16:50	**[B3.2] Delta inulin (advax[tm]): A new paradigm in vaccine adjuvants** N. Petrovsky, *Vaxine Pty Ltd, Australia*	**[B4.2] Cross-reactive neuraminidase-inhibiting antibodies elicited by immunization with recombinant neuraminidase proteins of H5N1 and pH1N1 influenza A viruses** S.C. Wu, *National Tsing Hua University, Taiwan*
16:50-17:05	**[B3.3] PLGA (85:15) Nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against *Brucella abortus* 544 infection: A promising alternate to traditional adjuvants** D. Singh*, R. Bhatnagar *Jawahar Lal Nehru University, India*	**[B4.3] A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against middle east respiratory syndrome coronavirus in non-human primates** K. Muthumani*[1], D.B. Weiner[1], D. Falzarano[2], E. Reuschel[1], C. Tingey[1], S. Flingai[1], D.O. Villarreal[1], M. Wise[1], A. Patel[1], A. Izmirly[1] *et al. [1]University of Pennsylvania School of Medicine, USA, [2]National Institute of Allergy and Infectious Diseases, USA, [3]University of Manitoba and Public Health Agency of*

		Canada, USA, [4]Inovio Pharmaceuticals Inc., USA, [5]NIH, USA, [6]University of Washington, USA, [7]University of South Florida Morsani College of Medicine, USA
17:05-17:20	**[B3.4] Exploring potent immunological regulation of interferon-inducible 25-hydroxycholesterol as a novel adjuvant for HIV vaccine** C.J. Sun*, T.J. Wu, L. Chen *Guangzhou Institutes of Biomedicine and Health (GIBH), China*	**[B4.4] Host immune status and parasite determinates influence the vaccine efficacy against Leishmania parasites** L. Soong*, C. Hay, Y. Liang, E. Carlsen, C. Henard, R. Tirbeni, G. Thaxton, J. Sun *University of Texas Medical Branch, USA*
17:20-17:35	**[B3.5] Innovative polymeric adjuvant for PCV2 vaccination** F. Bertrand[1], J.B. Arous[2], J. Gaucheron[2], S. Sunwoo[3], Y.S. Lyoo[3], O.A. Verkhovsky[4], L. Dupuis[2], S.L. Teo*[1] *[1] SEPPIC China, , China [2] SEPPIC, France [3] Konkuk University, South Korea [4]Diagnostic and Prevention Research Institute for Human and Animal Diseases, Russia*	**[B4.5] Development of a Chikungunya Vaccine Utilizing the Eilat Virus Platform** J.H. Erasmus*[1], F. Nasar[3], G. Leal[1], J. Kaelber[2], W. Chiu[2], V. Popov[1], D. Kim[4], H. Luo[1], T. Wang[1], S.C. Weaver[1] *[1]University of Texas Medical Branch, USA, [2]Baylor College of Medicine, USA, [3]U.S. Army Medical Research Institute of Infectious Diseases, USA, [4]University of Alabama, USA*
17:35-17:50	**[B3.6] TLR9 and STING Agonists Synergistically Induce Innate and Adaptive Type-II IFN** B. Temizoz*[1], E. Kuroda[1], K. Ohata[1], N. Jonai[2], K. Ozasa[2], K. Kobiyama[2], T. Aoshi[2], K.J. Ishii[1,2] *[1]Osaka University, Japan, [2]National Institute of Biomedical Innovation, Japan*	**[B4.6] A two-component DNA-prime/protein-boost vaccination strategy for eliciting long-term, protective t cell immunity against *Trypanosoma cruzi*** S. Gupta, N.J. Garg*, *University of Texas Medical Branch, USA*
17:50-18:05	**[B3.7]A novel approach to differentiate antibody response from vaccination and natural infection of flavivirus.** D.Y. Chao*[1], J.U. Galula[1], G.J. Chang[2] [1]National Chung-Hsing University, Taiwan, [2]Centers for Disease Control and Prevention, USA	**[B4.7] A multivalent Ebola GP DNA vaccine induces seroconversion after a single immunization and protects against lethal Guinea-Makona 2014 virus challenge in non-human primates.** A. Patel*[1], E.L. Resuchel[1], K.A. Kraynyak[2], T. Racine[3], J. Walters[1], J. Audet[3,4], M. Karuppiah[1], D.J. Shedlock[1], A. Bello[3], G. Soule[3], K.N. Tran[2], J. Yan[2], M. Yang[2], A. Khan[2], K. Tierney[3], X. Qiu[3], G.P. Kobinger[1,3,4], N.Y. Sardesai[2], D.B. Weiner[1]. [1]*University of Pennsylvania, USA* [2]*Inovio Pharmaceuticals, Plymouth Meeting, USA* [3]*Public Health Agency of Canada, Canada* [4]*University of Manitoba, Canada*
18:05-19:00	**Welcome Drinks Reception and Poster Session 1** ***Crystal Ballroom Foyer*** ***Sponsored by***	

Monday, 19 October 2015		
08:30-10:35	**Plenary Session 1: Vaccines against Viral Pathogens** **Session Chairs: Gavin Smith & Adolfo Garcia-Sastre** ***Crystal Ballroom 1&2***	
08:30-08:55	**[PLN1.1] The phylodynamics of H1N1/2009 influenza: From pandemic to seasonal influenza** Y.C.F. Su[1], J. Bahl[1,2], U. Joseph[1], K.M. Butt[1], H.A. Peck[3], E.S.C. Koay[4], L.L.E. Oon[5], I.G. Barr[3], D. Vijaykrishna[1,3], G.J.D. Smith*[1,3] *[1]Duke-NUS Graduate Medical School, Singapore, [2]The University of Texas, USA, [3]World Health Organisation Collaborating Centre for Reference and Research on Influenza, Australia, [4]National University Hospital, Singapore, [5]Singapore General Hospital, Singapore, [6]National University of Singapore, Singapore, [7]Duke University, USA*	
08:55-09:20	**[PLN1.2] Development of the Sanofi Pasteur dengue vaccine: Early development, efficacy studies & next steps** B. Guy*, O. Briand, J. Lang, M. Saville, N. Jackson, *Sanofi Pasteur, France*	
09:20-09:35	**[PLN1.3] Deep sequencing of the Yellow Fever vaccine strain 17D reveals low diversity compared to wild-type parent Asibi virus and population stability for primary and secondary seed lots of 17D vaccine** A.D.T. Barrett*, A. Beck, N. Collins, S.G. Widen, T. Wood, J.K. Thompson, *University of Texas Medical Branch, USA*	
09:35-09:50	**[PLN1.4] Immunization with a single recombinant hepatitis C virus envelope protein elicits pan-genotypic neutralizing antibodies in macaques and confers protection against viral challenge in mice** D. Li[1], M. von Schaewen[2], X. Wang[1], W. Tao[1], Y. Zhang[1], L. Li[1], B. Heller[2], A. Ploss[2], J. Zhong[1], Z. Huang*[1] et al *[1]Institut Pasteur of Shanghai, China, [2]Princeton University, USA*	
09:50-10:05	**[PLN1.5] Development of a novel genetically stable live-attenuated respiratory syncytial virus (RSV) vaccine that provides enhanced immunogenicity and thermal stability** C.C. Stobart*[1,2], C.A. Rostad[1,2], R.J. Pickles[3], Z. Ke[1,6], J. Meng[1,2], K. Sakamoto[4], A.L. Hotard[1,2], S. Lee[1,2], P.A. Piedra[5], B.E. Gilbert[5], E.R. Wright[1,2], M.L. Moore[1,2] *[1]Emory University School of Medicine, USA, [2]Children's Healthcare of Atlanta, USA, [3]University of North Carolina, USA, [4]University of Georgia, USA, [5]Baylor College of Medicine, USA, [6]Georgia Institute of Technology, USA*	
10:05-10:20	**[PLN1.6] Recombinant adeno-vaccine expressing Enterovirus 71-like particles against hand, foot, and mouth disease** Y.H. Chow*[1], Y.L. Tsou[1,] *[1]National Health Research Institutes, Taiwan, [2]China Medical University, Taiwan*	
10:20-10:35	**[PLN1.7] Generation of CAVA poliovirus strains for the development of an affordable and safe next generation inactivated poliovirus vaccine** B.P. Sanders*, I. de los Rios, V. van Hoek, D.E. Matas, J. Custers, H. Schuitemaker *Janssen Infectious Diseases and Vaccines, The Netherlands*	
10:35-11:00	**Refreshment Break** *Crystal Ballroom Foyer*	
11:00-12:40	**Breakout Session 5: Therapeutic Vaccines** **Session Chairs: Ian Frazer and Randy Albrecht** ***Crystal Ballroom 1***	**Breakout Session 6: Vaccine Delivery** **Session Chairs: Anna-Lise Williamson & Heather Wilson** ***Crystal Ballroom 2***

	Sponsored by	
11:00-11:20	**[B5.1] Immunological interventions for anogenital viral infections** I.H. Frazer, *Translational Research Institute, Australia*	**[B6.1] Dissolving polymer microneedle immunization with trivalent inactivated influenza vaccine** E.V. Vassilieva[1], H. Kalluri[2], D. McAllister[2], M. T. Taherbhai[1], E.S. Esser[1], W.P. Pewin[2], J.A. Pulit-Penaloza[1,3], M.R. Prausnitz[2], R.W. Compans[1], I. Skountzou*[1] [1]*Emory University School of Medicine, USA,* [2]*Georgia Institute of Technology, USA,* [3]*Centers for Disease Control, USA*
11:20-11:40	**[B5.2] The optimization and development of a novel therapeutic DNA vaccine** H-T. Jin, *BioDion, Inc, Republic of Korea*	**[B6.2] Capripoxviruses as host-restricted vaccine vectors** K. Offerman[1], N. Douglass[1], A. Deffur[1], R.J. Wilkinson[1], A-L Williamson*[1] [1]*University of Cape Town, South Africa,* [2]*Groote Schuur Hospital, South Africa*
11:40-11:55	**[B5.3] Human monoclonal antibody 100F4 cross-neutralizes and cross-protects newly emerging highly pathogenic avian influenza H5N8 virus *in vivo.*** H. Ren[1]*, G. Wang[1], S. Wang[1], P. Buchy[2], G. Cheng[3], V. Deubel[2], and P. Zhou[1]. [1]*Chinese Academy of Sciences, China,* [2]*Institut Pasteur in Cambodia, Cambodia,* [3]*University of California Los Angeles, USA*	**[B6.3] *In vivo* visualization of a protective nanovaccine formulation** A. Seth, N. Wibowo, L.H.L. Lua, A.P.J. Middelberg* *The University of Queensland, Australia*
11:55-12:10	**[B5.4] Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma** M. Tagliamonte[1], A. Petrizzo[1], M. Napolitano[1], C. Arra[1], P. Maiolino[1], M. Tornesello[1], L. Aurisicchio[2], G. Ciliberto[1], F.M. Buonaguro[1], L. Buonaguro*[1] [1]*IRCCS, Italy,* [2]*Takis, S.R.L., Italy*	**[B6.4] DNA-launched attenuated RNA vaccines** I.S. Lukashevich*[1], I. Tretyakova[2], P. Pushko[2] [1]*University of Louisville, USA,* [2]*Medigen, Inc, USA*
12:10-12:25	**[B5.5] A novel therapeutic vaccine against tuberculosis in the monkey model, preclinical study and clinical trial** M. Okada*[1], T. Nakajima[2], Y. Kaneda[3], Y. Inoue[1], K. Tomono[3], A. Kumanogoh[3], K. Tsuyuguchi[1], S. Syoji[4], A. Mikami[5], T. Saito[6] et al [1]*National Hospital Organization Kinki-chuo Chest Medical Center, Japan,* [2]*Genomidea Co., Japan,* [3]*Osaka University, Japan,* [4]*NHO Tokyo Hospital, Japan,* [5]*Tokai University,*	**[B6.5] Parainfluenza virus 5 (PIV5) is a promising live vector for vaccine development** B. He, *University of Georgia, USA*

	Japan, *[6]NHO Ibaraki-higashi Hospital, Japan*	
12:25-12:40	**[B5.6] Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease** H-F. Tseng*, Y. Luo, J. Shi, S. Tartof, J. Sim, S. Jacobsen, *Kaiser Permanente Southern California, USA*	**[B6.6] Measles and Rubella Vaccination Using a Microneedle Patch** M.L. Collins*[1], J.C. Joyce[2], M. Chen[1], P.A. Rota[1], M.R. Prausnitz[2, 1]*Centers for Disease Control and Prevention, USA,* *[2]Georgia Institute of Technology, USA*
12:40-14:00	**Lunch** *Crystal Ballroom Foyer*	
13:00-14:00	***Vaccine* Author Workshop: How to get published!** **Greg Poland, Editor-in-Chief of *Vaccine* and Alina Helsloot, Publisher of *Vaccine*** *Crystal Ballroom 1*	
14:00-15:00	**ISV Annual General Meeting (open)** *Crystal Ballroom 2*	
15:00-16:00	**Refreshments and Poster Session 2** *Crystal Ballroom Foyer*	
16:00-18:30	**Breakout Session 7: Bacterial Vaccines** **Session Chairs: Florian Marks and Linda Klavinskis** ***Crystal Ballroom 1***	**Breakout Session 8: Vaccines for Respiratory Pathogens** **Session Chairs: Paul Zhou and Anders Fomsgaard** ***Crystal Ballroom 2***
16:00-16:20	**[B7.1] Invasive *Salmonella* infections in Africa and implications for vaccination programs** F. Marks, *International Vaccine Institute, Korea*	**[B8.1] Hemagglutinin (HA)-based "universal" vaccine development against influenza viruses** P. Zhou, *Chinese Academy of Sciences, China*
16:20-16:40	**[B7.2] Next generation protein based *Streptococcus pneumoniae* vaccines** M.E. Pichichero, *Rochester General Hospital Research Institute, USA*	**[B8.2] Polyvalent influenza-A DNA vaccine for pigs and humans** A. Fomsgaard*[1], M. Borggren[1], J. Nielsen[1], I. Karlsson[1], J. Williams[2] *[1]Statens Serum Institut, Denmark,* *[2]Nature Technology Corporation, USA*
16:40-17:00	**[B7.3] Deletion of specific small RNAs enhances the vaccine cross-protection of an *rfaH* mutant of *Salmonella enterica* serovar Typhimurium** B.L. Bearson*, *S.M.D. Bearson. USDA, ARS, USA*	**[B8.3] Better influenza vaccines: looking beyond the viral hemagglutinin** X. Saelens[1,2 1]*VIB, Belgium,* *[2]Ghent University, Belgium*
17:00-17:15	**[B7.4] Induction of cross-reactive multifunctional CD4+T cells in healthy volunteers immunized with the live oral typhoid vaccine Ty21a** R. Wahid*, S. Fresnay, M.M. Levine, M.B. Sztein *University of Maryland School of Medicine, USA*	**[B8.4] Design and characterization of a COBRA hemagglutinin vaccine for H1N1 influenza viruses.** D.M. Carter*[1], C.A. Darby[1], C.J. Crevar[2], B.C. Lefoley[1], T. Alefantis[2], H. Kleanthous[2], T.M. Ross[1 1]*University of Georgia, USA,* *[2]Sanofi-Pasteur, USA*
17:15-17:30	**[B7.5] Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a**	**[B8.5] Influenza virus hemagglutinin stalk-based immunity in ferrets** F. Krammer[1], R. Nachbagauer[1,2], P. Palese[1], A. García-Sastre[1], R.A. Albrecht*[1]

	murine model BaoZhong Zhang [1 2], YanHong Hua [1], Bin Yu [1], Candy ChoiYi Lau [2], JianPiao Cai [2] SongYue Zheng [1], WingCheong Yam [2], Richard Yi-Tsun Kao [2], Konghung SZE [2], Bo-Jian Zheng [2], Kwok-Yung Yuen [2] , Jian-Dong Huang*[1], *[1] Department of Biochemistry, The University of Hong Kong, , Hong Kong, [2] Department of Microbiology, The University of Hong Kong, , Hong Kong, China*	*[1]Icahn School of Medicine, USA, [2]University of Vienna, Austria*
17:30-17:45	**[B7.6] Protection against influenza-bacterial co-infection by M2e universal influenza vaccine.** I. Chrstopoulou[1,2], W. Fiers[1,2], X. Saelens*[1,2], *[1]VIB, Belgium, [2]Ghent University, Belgium*	**[B8.6] Broad immune response induced by plant-made influenza VLP vaccines** N. Landry*[1], S. Trépanier[1], E. Aubin[1], S. Pillet[1,2], and B.J. Ward[1,2] *[1]Medicago Inc., Quebec, Quebec, Canada; [2]Research Institute of the McGill University Health Centre University, Montreal, Quebec, Canada*
17:45-18:00	**[B7.7] Multiple non-vaccine serotypes of streptococcus pneumoniae emerge during the 7-valent (PCV7) and 13-valent (PCV13) pneumococcal conjugate vaccination - Rochester, NY - 2006-2014** J.R. Casey*[1], R. Kaur[2], M.E. Pichichero[1] *[1]Legacy Pediatrics, USA, [2]Rochester General Hospital Research Institute, USA*	**[B8.7] Bioluminscent influenza A viruses for evaluating influenza virus vaccine** W.Q. Pan*[1], L.Q. Feng[2], C.F. Li[1], L. Chen[1,2], *[1]State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou; [2], Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China*
18:00-18:15	**[B7.8] Affordable Conjugate Vaccines: Efficient chemistry and Low Cost CRM_{197} Carrier Protein.** A. Lees[1], S. Jain*[2], N. Oganesyan[1], *[1]Fina Biosolutions LLC., USA* *[2]Novo Biosolutions Inc., USA*	**Withdrawn**
18:15-18:30	**[B7.9] Serotype distribution of *Streptococcus pneumoniae* in children with invasive diseases in Turkey: 2008-2014** M. Ceyhan*[1], Y. Ozsurekci[1], N. Gurler[2], L. Oksuz[2], S. Aydemir[3], S. Ozkan[4], S. Yuksekkaya[5], M. Keser Emiroglu[6], M. Gultekin[7], A. Yaman[8] *et al. [1]Hacettepe University, Turkey, [2]Istanbul University, Turkey, [3]Ege University, Turkey, [4]Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital, Turkey, [5]Konya Training and Research Hospital, Turkey, [6]Selcuk University, Turkey, [7]Akdeniz University, Turkey, [8]Cukurova University, Turkey*	**[B8.9] Broadly neutralizing antibodies induced by multivalent inactivated rhinovirus** S. Lee*[1,2], M.T. Nguyen[1], M.G. Currier[1,2], M.L. Moore[1,2] *[1]Emory University Department of Pediatrics, USA, [2]Children's Healthcare of Atlanta, USA*

19:15	**Depart the front of the Hotel to go to the Gala Dinner (ticket holders only)**
19:30-23:00	**Congress Gala Dinner (ticket holders only)**
Tuesday, 20 October 2015	
08:00-08:30	**Congress Registration**
08:30-10:30	**Plenary Session 2: Clinical Trials** **Session Chairs: Shan Lu and Allan Saul** ***Crystal Ballroom 1&2***
08:30-08:50	**[PLN2.1] Clinical proof-of-concept of SBVGH Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) vaccine administered by intramuscular route** A. Saul**,** *Novartis Vaccines for Global Health, Italy*
08:50-09:10	**[PLN2.2] Sub-Saharan Africa's contribution to HIV vaccine and cure research: a case study** H.N. Kibuuka, *Makerere University Walter Reed Project, Uganda*
09:10-09:30	**[PLN2.3] Overview of the effectiveness and safety of the oral human rotavirus vaccine, rotarix; 10 years after its introduction: delivering the promise of protection against rotavirus diarrheoa** B. Benninghoff, *GSK Global Medical Affairs, Belgium*
09:30-09:45	**[PLN2.4] Enhanced H7N9 vaccine immunogenicity engineered through immunoinformatic design** A.S. De Groot*[1,2], L. Moise[1,2], M. Ato[3], Y. Takahashi[3], A. Nithichanon[3,4], T. Ross[5], B. Martin[1] *[1]EpiVax, Inc., USA, [2]University of Rhode Island, USA, [3]National Institute of Infectious Diseases, Japan, [4]Khon Kaen University, Thailand, [5]University of Georgia, USA*
09:45-10:00	**[PLN2.5] Post hoc analysis of a randomized double-blind trial of correlation of low varicella zoster vaccine responses by concomitant administration of 23-valent pneumococcal polysaccharide vaccine in elderly patients with diabetes** A. Hata*[1], T. Ishioka[2,3], K. Oishi[2], T. Katayama[4], T. Ohkubo[5] *[1]The Tazuke Kofukai Medical Research Institute, Japan, [2]National Institute of Infectious Diseases, Japan, [3]Takasaki General Public Health Center, Japan, [4]Himeji Dokkyo University, Japan, [5]Teikyo University School of Medicine, Japan*
10:00-10:15	**[PLN2.6] Safety and immunogenicity of recombinant acellular pertussis vaccine (ap) and combined tetanus, diphtheria, recombinant acellular pertussis (tdap) vaccine in 18-35 years old healthy adults in Thailand** C. Sirivichayakul*[1], P. Chanthavanich[1], K. Limkittikul[1], C-A. Siegrist[2], J. Petre[3], W. Wijagkanalan[3], P. Chinwangso[3], M. Chauhan[3], H-T. Pham[3], S. Viviani[3] *[1]Mahidol University, Thailand, [2]Medicine University of Geneva, Switzerland, [3]BioNet-Asia Co., Thailand*
10:15-10:30	**[PLN2.7] Acquisition of vaginal colonization with group B Streptococcus in pregnant women induces higher antibody responses to protein antigens than rectal colonization** S. Dzanibe*[1,2], P.V. Adrian[1,2], G. Kwatra[1,2], S.Z. Kimaro-Mlacha[1,2], S.A. Madhi[2,3] *[1]University of the Witwatersrand, South Africa, [2]Respiratory and Meningeal Pathogen Research Unit,* *South Africa, [3]National Institute of Communicable Diseases, South Africa*
10:30-11:00	**Refreshment Break** *Crystal Ballroom Foyer*
11:00-12:55	**Breakout Session 9: Vaccine Policy,**	**Breakout Session 10: Mucosal**

	Production, and Manufacturing ***Supported by Japanese Society for Vaccines*** **Session Chairs: Ken Ishii and Steve Black** ***Crystal Ballroom 1***	**Vaccination and Immunity** **Session Chairs: Hideki Hasegawa and Bin Wang** ***Crystal Ballroom 2***
11:00-11:20	**[B9.1] Recent progress and concerns regarding the Japanese immunization program: addressing the "vaccine gap"** A. Saitoh, *Niigata University Graduate School of Medical and Dental Sciences, Japan*	**[B10.1] Development of intranasal inactivated influenza vaccine and immune system induced by the vaccine** H.H. Hasegawa, *National Institute of Infectious Diseases, Japan*
11:20-11:40	**[B9.2] Achievement of measles elimination in Japan, March 2015** T. Sunagawa, *National Institute of Infectious Diseases, Japan*	**[B10.2] Oral CTL vaccine against HIV-1 using a CTP-integrated sabin 1 poliovirus-derived mucosal vector RPS-VAX system.** M-H. Kang*, Y-J. Park, J. Lee, S-S. Han, M-S. Cha, E. Lee, Y-S. Bae, *Sungkyunkwan University, Republic of Korea*
11:40-11:55	**[B9.3] Budget impact of introducing inactivated poliomyelitis vaccine (IPV): a case study of child immunization program of India** M.M. Khan*[1], S. Sharma[2], B. Tripathi[4], F.P. Alvarez[3, 1]*[1]University of South Carolina, USA, [2]Sanofi Pasteur, India, [3]Sanofi Pasteur, France, [4]Independent Consultant, India*	**[B10.3] Tablet vaccine platform elicits neutralizing and mucosal antibodies without being impacted by preexisting immunity** S.N. Tucker, J.D. Lindbloom, L. Kim*, J. Martinez, K. Hodgson, C.D. Scallan, D. Liebowitz *Vaxart, Inc., USA*
11:55-12:10	**[B9.4] Novel adjuvant L-pampo and its applications** J.S. Yum*, H.J. Jo, S.K. Baek, E.J. Jung, S.K. Jung, B.M. Kim, B.C. Ahn, *R&D Center, CHA Vaccine Institute, Republic of Korea*	**[B10.4] Safety of rotavirus vaccine for very low birth weight infants in NICU** F. Hattori*[1], K. Sugata[1], M. Ihira[2], H. Hiramatsu[3], R. Suzuki[3], K. Taniguchi[1], S. Yamada[3], T. Yoshikawa[1 1]*[1]Fujita Health University School of Medicine, Japan, [2]Fujita Health University, Japan, [3]Fujita Health University Hospital, Japan*
12:10-12:25	**[B9.5] Introducing non-traditional vaccines in Indonesia: rotavirus and hepatitis A as reference cases** A.A. Suwantika*[1,2], K. Lestari[1], M.J. Postma[2] *[1]Universitas Padjadjaran, Indonesia, [2]University of Groningen, The Netherlands*	**[B10.5] Neutrophils regulation of mucosal IgA responses to experimental sublingual vaccines** J. Jee, E. Kim, E. Cormet-boyaka, T.L. Martin, H.E. Steiner, P.N. Boyaka*, *The Ohio State University, USA*
12:25-12:40	**[B9.6] Estimating resource needs for achieving adult vaccination targets in the USA** M.M. Khan*[1], V. Heboyan[2 1]*[1]University of South Carolina, USA, [2]Georgia Regents University, USA*	**[B10.6] Development of liposome-based vaccine formulations to enhance the longevity of vaccine-induced immunity against foot-and-mouth disease virus** R.O. Braun*[1,4], L. Brunner[2], G. Auray[1], A. Baumann[1], O. García-Nicolás[1], S. Python[1],

		B. Zumkehr[1], M.H. Stoffel[3], C. Barnier-Quer[2], A. Summerfield[1] et al *[1]Institute of Virology and Immunology, Switzerland, [2]University of Lausanne, Switzerland, [3]University of Bern, Switzerland, [4]University of Bern, Switzerland*
12:40-12:55	**[B9.7] The native confirmation of Influenza haemagglutinin as a surrogate for vaccine potency** A. Farnsworth*, M. Lemieux, S. Li. *Centre for Biologics Evaluation, Biologics and Genetic Therapies Directorate, Health Canada, Canada*	**[B10.7] Application of HP-beta-CD for mucosal adjuvant** T. Kusakabe*[1,2], E. Kuroda[2], K.J. Ishii[1,2], *[1]Laboratory of Adjuvant Innovation, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN), Japan, [2]Osaka University, Japan*
12:55-14:00	**Lunch and Poster Viewing** *Crystal Ballroom Foyer*	
13:00-14:00	**Career Development Workshop: Identifying and Achieving your Dream Job** *Crystal Ballroom 1*	
14:00-14:20	**Edward Jenner Poster Prize Ceremony**	
14:20-15:00	**Plenary Session 3: Closing Keynotes** **Session Chairs: Ted M. Ross and Joon Haeng Rhee** ***Crystal Ballroom 1&2***	
14:20-14:40	**[PLN3.1] The costs and effectiveness of large pre-licensure safety studies: time for a new paradigm** S. Black *University of Cincinnati Children's Hospital, USA*	
14:40-15:00	**[PLN3.2] Universal influenza vaccine approach: options and obstacles** Y.H. Jang[1], B.L. Seong*[1,2] *[1]Life Science & Biotechnology [2]Vaccine Translational Research Center, Yonsei University, Republic of Korea*	
15:00-15:15	**Closing Summary: Margaret Liu, Joon Haeng Rhee, and Ted M. Ross, Congress Co-Chairs**	